Diabetes is a long-term condition where too much sugar stays in the blood. If not managed well, it can get worse over time, ...

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

a popular weight-loss drug containing semaglutide, shows promising results in treating liver diseases like MASH. The study, published in the New England Journal of Medicine, involved over 800 ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide ... in weight in the REDEFINE 1 study over 68 weeks that fell short of Novo Nordisk's hope of a 25% loss.

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

Ozempic, a diabetes drug, shows promise for liver disease. Research indicates it can reverse non-alcoholic steatohepatitis. A ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Ebn Sina Medical, a subsidiary of Aamal Company, and Danish healthcare major Novo Nordisk have launched the weight loss ...

Research revealed that medications widely used for diabetes and obesity may offer significant benefits for patients with ...

Last year, more than 16 million people googled 'semaglutide' - sold under the brand names Wegovy and Ozempic - as demand for ...

which studied 25 milligram dose of oral semaglutide compared to placebo in 307 adults with obesity with one or more comorbidities. The company is also studying weight-loss pill amycretin ...

With pharmaceutical GLP-1 drugs like semaglutide in high demand, Metamorphx offers a plant-based alternative designed to ...